Taysha Gene Therapies (TSHA) Short term Debt (2020 - 2023)
Taysha Gene Therapies' (TSHA) quarterly Short term Debt came in at $140.5 million in Q3 2023, up 234123.33% quarter-over-quarter from $60000.0 in Q3 2020.
Taysha Gene Therapies (TSHA) Short term Debt (2020 - 2023) Analysis & Trends
Taysha Gene Therapies has disclosed Short term Debt across 2 years of filings, most recently posting $140.5 million for Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Taysha Gene Therapies | 2.36 Bn | 2.36 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | 140.53 Mn |
| Sep 30, 2020 | 60,000.00 |